Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Early B cell changes predict autoimmunity following combination immune checkpoint blockade.

Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

J Clin Invest. 2018 Feb 1;128(2):715-720. doi: 10.1172/JCI96798. Epub 2018 Jan 8.

2.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

PMID:
29208646
3.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

4.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

PMID:
28595336
5.

Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.

Lazova R, Pornputtapong N, Halaban R, Bosenberg M, Bai Y, Chai H, Krauthammer M.

Mod Pathol. 2017 May;30(5):640-649. doi: 10.1038/modpathol.2016.237. Epub 2017 Feb 10.

6.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

JCI Insight. 2016 Dec 22;1(21):e88955. doi: 10.1172/jci.insight.88955.

7.

A generic, cost-effective, and scalable cell lineage analysis platform.

Biezuner T, Spiro A, Raz O, Amir S, Milo L, Adar R, Chapal-Ilani N, Berman V, Fried Y, Ainbinder E, Cohen G, Barr HM, Halaban R, Shapiro E.

Genome Res. 2016 Nov;26(11):1588-1599. Epub 2016 Aug 24.

8.

GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.

Lim YH, Bacchiocchi A, Qiu J, Straub R, Bruckner A, Bercovitch L, Narayan D; Yale Center for Mendelian Genomics, McNiff J, Ko C, Robinson-Bostom L, Antaya R, Halaban R, Choate KA.

Am J Hum Genet. 2016 Aug 4;99(2):443-50. doi: 10.1016/j.ajhg.2016.06.010. Epub 2016 Jul 28.

9.

Germline MC1R status influences somatic mutation burden in melanoma.

Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP, Alexandrov LB, Pornputtapong N, Halaban R, Krauthammer M, Cui R, Timothy Bishop D, Adams DJ.

Nat Commun. 2016 Jul 12;7:12064. doi: 10.1038/ncomms12064.

10.

RASopathy Gene Mutations in Melanoma.

Halaban R, Krauthammer M.

J Invest Dermatol. 2016 Sep;136(9):1755-9. doi: 10.1016/j.jid.2016.05.095. Epub 2016 May 25. Review.

11.

AMPK promotes tolerance to Ras pathway inhibition by activating autophagy.

Sanduja S, Feng Y, Mathis RA, Sokol ES, Reinhardt F, Halaban R, Gupta PB.

Oncogene. 2016 Oct 6;35(40):5295-5303. doi: 10.1038/onc.2016.70. Epub 2016 Apr 4.

PMID:
27041569
12.

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R.

Nat Genet. 2015 Sep;47(9):996-1002. doi: 10.1038/ng.3361. Epub 2015 Jul 27.

13.

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA.

Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28.

14.

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA.

Cancer Res. 2015 Apr 1;75(7):1399-412. doi: 10.1158/0008-5472.CAN-14-2785. Epub 2015 Feb 24.

15.

Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure.

Premi S, Wallisch S, Mano CM, Weiner AB, Bacchiocchi A, Wakamatsu K, Bechara EJ, Halaban R, Douki T, Brash DE.

Science. 2015 Feb 20;347(6224):842-7. doi: 10.1126/science.1256022.

16.

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.

J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.

17.

RAC1 and melanoma.

Halaban R.

Clin Ther. 2015 Mar 1;37(3):682-5. doi: 10.1016/j.clinthera.2014.10.027. Epub 2014 Nov 22.

18.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

19.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

20.

Rare SF3B1 R625 mutations in cutaneous melanoma.

Kong Y, Krauthammer M, Halaban R.

Melanoma Res. 2014 Aug;24(4):332-4. doi: 10.1097/CMR.0000000000000071.

21.

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.

Choi J, Landrette SF, Wang T, Evans P, Bacchiocchi A, Bjornson R, Cheng E, Stiegler AL, Gathiaka S, Acevedo O, Boggon TJ, Krauthammer M, Halaban R, Xu T.

Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62. doi: 10.1111/pcmr.12197. Epub 2014 Jan 6.

22.

Clonal growth of human melanocytes using cell-free extracellular matrix.

Zhang R, Premi S, Kilic SS, Bacchiocchi A, Halaban R, Brash DE.

Pigment Cell Melanoma Res. 2013 Nov;26(6):925-7. doi: 10.1111/pcmr.12159. Epub 2013 Sep 19. No abstract available.

23.

RAC1P29S is a spontaneously activating cancer-associated GTPase.

Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):912-7. doi: 10.1073/pnas.1220895110. Epub 2013 Jan 2.

24.

Integrated analysis of tumor samples sheds light on tumor heterogeneity.

Parisi F, Micsinai M, Strino F, Ariyan S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y.

Yale J Biol Med. 2012 Sep;85(3):347-61. Epub 2012 Sep 25.

25.

Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.

Ha BH, Davis MJ, Chen C, Lou HJ, Gao J, Zhang R, Krauthammer M, Halaban R, Schlessinger J, Turk BE, Boggon TJ.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16107-12. doi: 10.1073/pnas.1214447109. Epub 2012 Sep 17.

26.

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.

Nat Genet. 2012 Sep;44(9):1006-14. doi: 10.1038/ng.2359. Epub 2012 Jul 29.

27.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

28.

Chitinase-like proteins in lung injury, repair, and metastasis.

Lee CG, Dela Cruz CS, Ma B, Ahangari F, Zhou Y, Halaban R, Sznol M, Elias JA.

Proc Am Thorac Soc. 2012 May;9(2):57-61. doi: 10.1513/pats.201112-056MS.

29.

In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP.

Cell. 2011 Oct 14;147(2):382-95. doi: 10.1016/j.cell.2011.09.032. Erratum in: Cell. 2011 Nov 11;147(4):948.

30.

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8. doi: 10.1073/pnas.1110814108. Epub 2011 Sep 20.

31.

Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies.

Parisi F, Ariyan S, Narayan D, Bacchiocchi A, Hoyt K, Cheng E, Xu F, Li P, Halaban R, Kluger Y.

BMC Genomics. 2011 May 11;12:230. doi: 10.1186/1471-2164-12-230.

32.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

33.

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

34.

Plasma markers for identifying patients with metastatic melanoma.

Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R.

Clin Cancer Res. 2011 Apr 15;17(8):2417-25. doi: 10.1158/1078-0432.CCR-10-2402. Epub 2011 Apr 12.

35.

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".

Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM.

J Transl Med. 2011 Mar 26;9:32. doi: 10.1186/1479-5876-9-32.

36.

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ.

Oncogene. 2011 Mar 31;30(13):1542-50. doi: 10.1038/onc.2010.536. Epub 2010 Nov 29.

37.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

38.

Meenhard Herlyn.

Halaban R.

Pigment Cell Melanoma Res. 2010 Apr;23(2):287. doi: 10.1111/j.1755-148X.2010.00683.x. No abstract available.

PMID:
20394680
39.

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.

Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M.

Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200. doi: 10.1111/j.1755-148X.2010.00685.x. Epub 2010 Feb 10. Erratum in: Pigment Cell Melanoma Res. 2012 May;25(3):402.

40.

Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.

Rubinstein JC, Tran N, Ma S, Halaban R, Krauthammer M.

BMC Med Genomics. 2010 Feb 9;3:4. doi: 10.1186/1755-8794-3-4.

41.

Genome-wide screen of promoter methylation identifies novel markers in melanoma.

Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM.

Genome Res. 2009 Aug;19(8):1462-70. doi: 10.1101/gr.091447.109. Epub 2009 Jun 2.

42.

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.

Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, Tran N, Zhang W, Picardo M, Enghild JJ.

PLoS One. 2009;4(2):e4563. doi: 10.1371/journal.pone.0004563. Epub 2009 Feb 23.

43.

MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment.

Pelizzola M, Koga Y, Urban AE, Krauthammer M, Weissman S, Halaban R, Molinaro AM.

Genome Res. 2008 Oct;18(10):1652-9. doi: 10.1101/gr.080721.108. Epub 2008 Sep 2.

44.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL.

Mod Pathol. 2008 Sep;21(9):1121-9. doi: 10.1038/modpathol.2008.100. Epub 2008 Jun 13.

45.

Metastatic peritoneal neurocutaneous melanocytosis.

Cajaiba MM, Benjamin D, Halaban R, Reyes-Múgica M.

Am J Surg Pathol. 2008 Jan;32(1):156-61.

PMID:
18162783
46.

Roadmap for new opportunities in melanoma research.

Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D.

Semin Oncol. 2007 Dec;34(6):566-76.

PMID:
18083380
47.

XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway.

Straszewski-Chavez SL, Visintin IP, Karassina N, Los G, Liston P, Halaban R, Fadiel A, Mor G.

J Biol Chem. 2007 Apr 27;282(17):13059-72. Epub 2007 Feb 28.

48.

Rab33A: characterization, expression, and suppression by epigenetic modification.

Cheng E, Trombetta SE, Kovacs D, Beech RD, Ariyan S, Reyes-Mugica M, McNiff JM, Narayan D, Kluger HM, Picardo M, Halaban R.

J Invest Dermatol. 2006 Oct;126(10):2257-71. Epub 2006 Jun 29.

49.

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.

McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM.

Clin Cancer Res. 2006 Jun 15;12(12):3856-63.

50.

Melanocyte and keratinocyte carcinogenesis: p53 family protein activities and intersecting mRNA expression profiles.

Kulesz-Martin M, Lagowski J, Fei S, Pelz C, Sears R, Powell MB, Halaban R, Johnson J.

J Investig Dermatol Symp Proc. 2005 Nov;10(2):142-52. Review.

Supplemental Content

Loading ...
Support Center